Selected Publications
Zhang W, Maeser D, Lee A, Huang Y, Gruener RF, Abdelbar IG, Jena S, Patel AG, Huang RS. Integration of pan-cancer cell line and single-cell transcriptomic profiles enables inference of therapeutic vulnerabilities in heterogeneous tumors. Cancer Res 84(12):2021-2033, 2024.
Chapple RH, Liu X, Natarajan S, Alexander MIM, Kim Y, Patel AG, LaFlamme C, Pan M, Wright WC, Lee H-M, Zhang Y, Lu M, Koo SC, Long C, Harper J, Savage C, Johnson MD, Confer T, Akers WJ, Dyer MA, Sheppard H, Easton J, Geeleher P. An unsupervised learning approach uncovers divergent mesenchymal-like gene expression programs across human neuroblastoma tumors, preclinical models, and chemotherapy-exposed tumors. Genome Biol 25(1):161., 2024.
Danielli S, Wei Y, Dyer MA, Stewart E, Wachtel M*, Schäfer B*, Patel AG*, Langenau D*. Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma. Nat Commun 15: 6307, 2024. (*co-corresponding authors)
Sengupta S, Das S, Crespo AC, Cornel AM, Patel AG, Mahadevan NR, Campisi M, Ali AK, Sharma B, Rowe JH, Huang H, Debruyne DN, Cerda ED, Krajewska M, Dries R, Chen M, Zhang S, Soriano L, Cohen MA, Versteeg R, Jaenisch R, Spranger S, Romee R, Miller BC, Barbie DA, Nierkens S, Dyer MA, Lieberman J, George RE. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Nat Cancer 3(10):1228-1246, 2022.
Zeineldin M, Patel AG, Dyer MA. Neuroblastoma: When Differentiation Goes Awry. Neuron 110(18):2916-2928, 2022.
Patel AG*, Chen X*, Huang X*, Clay MR, Komarova N, Krasin MJ, Pappo A, Tillman H, Orr BA, McEvoy J, Gordon B, Blankenship K, Reilly C, Zhou X, Norrie J, Karlstrom A, Yu J, Wodarz D, Stewart E, Dyer MA. The Myogenesis Program Drives Clonal Selection and Drug Resistance in Rhabdomyosarcoma. Dev Cell 27(10):1226-1240, 2022. *co-first authors
Honnell V, Norrie JL, Patel AG, Ramirez C, Zhang J, Lai Y-H, Wan S, Dyer MA. Identification of a modular super-enhancer in retinal development. Nat Commun 13:253, 2022.
Clay M*, Patel A*, Tran Q, Hedges DJ, Cheng T, Stewart E, Charville G, Cline C, Dyer MA, Orr BA*. Methylation profiling reveals novel molecular classes of rhabdomyosarcoma. Sci Rep 11:22213, 2021. *co-first authors
Durbin AD, Wang T, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, Mariani L, Shendy NAM, Nance S, Patel AG, Shao Y, Mundada M, Maxham L, Park PMC, Sigua LH, Morita K, Conway AS, Robichaud AL, Perez-Atayde AR, Bikowitz MJ, Quinn TR, Wienst OG, Easton J, Schönbrunn E, Bulyk M, Abraham BJ, Stegmaier K, Look AT, Qi J. EP300 selectively controls the enhancer landscape of MYCN- amplified neuroblastoma. Cancer Discov 12(3):730-751, 2021.
Nguyen R*, Patel AG*, Griffiths LM, Dapper J, Stewart EA, Houston J, Johnson M, Akers WJ, Furman, WL, Dyer MA. Next generation humanized patient-derived xenograft mouse model for preclinical antibody studies in neuroblastoma. Cancer Immunol Immunother 70(3):721-732, 2021. *co-first authors
Slyper M, Porter CBM, Ashenberg O, Waldman J, Drokhlyansky E, Wakiro I, Smillie C, Smith-Rosario G, Wu J, Dionne D, Vigneau S, Jané-Valbuena J, Tickle TL, Napolitano S, Su M, Patel AG, Karlstrom A, Gritsch S, Nomura M, Waghray A, Gohil SH, Tsankov AM, Jerby-Arnon L, Cohen O, Klughammer J, Rosen Y, Gould J, Nguyen L, Hofree M, Tramontozzi PJ, Li B, Wu CJ, Izar B, Haq R, Hodi FS, Yoon CH, Hata AN, Baker SJ, Suvà ML, Bueno R, Stover EH, Clay MR, Dyer MA, Collins NB, Matulonis UA, Wagle N, Johnson BE, Rotem A, Rozenblatt-Rosen O, Regev A. A single-cell and single-nucleus RNA-seq toolbox for fresh and frozen human tumors. Nat Med 26(5):792-802, 2020.
Last update: August 2024